Business Context and Reporting Period
Protalix Biotherapeutics, Inc. filed this Form 8-K on January 10, 2019, to report the results of a Special Meeting of Stockholders held on the same date. The Company is incorporated in Delaware and maintains its principal executive offices in Carmiel, Israel.
Key Financial Metrics
This filing is a current report regarding a corporate governance matter and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data.
Material Changes
The primary material event reported is the stockholder approval of an amendment to the Company's Certificate of Incorporation. This amendment increases the number of authorized shares of common stock, par value $0.001 per share, from 250,000,000 to 350,000,000.
Voting Results and Management Commentary
Stockholders voted on the proposal to increase authorized shares with the following results:
- For: 74,755,268 votes
- Against: 14,044,511 votes
- Abstain: 373,156 votes
The filing does not provide additional management commentary, forward-looking guidance, risk factors, or contingencies beyond the reporting of the vote.
Investor Verification Checklist
- Verify the effective date of the amended Certificate of Incorporation with the Delaware Secretary of State.
- Review the Company's most recent 10-K or 10-Q filings for current financial health, as this 8-K contains no financial data.
- Assess the potential dilution impact of the increased authorized share count on future capital raising activities.